ACE-LY-003: An Open Label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkins Lymphoma

Summary

To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL.

More information